Vaccine Makers Rise Amid Bird Flu Vaccine Hope After First U.S. Death
Vaccine makers rose after the first bird flu death was reported in the U.S.
Novavax up 14%, Moderna up 12%, CureVac up 11%, BioNTech up 5%, Pfizer up 2%.
Moderna is one of a few drugmakers currently developing a vaccine for the H5N1 bird flu, which is spreading rapidly through farms and wild animals in North America.
As of Jan. 6, there have been 66 confirmed human cases of H5N1 bird flu in the U.S. since 2024 and 67 since 2022, according to the Centers for Disease Control and Prevention.
Pfizer and GSK in partnership with CureVac are also developing mRNA vaccines for bird flu.
CureVac, a Germany-based biotech with a market cap of just under $1 billion, rose in Tuesday trading after a 23% gain Monday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。
熱議股票
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10